📊 SGMT Key Takeaways
Is Sagimet Biosciences Inc. (SGMT) a Good Investment?
Sagimet operates as an unprofitable early-stage biotech with $2M in annual revenue against $51M in net losses and $45.6M in operating cash burn, providing less than one year of runway with current $35M cash reserves. The company's operating and net margins of -2844% and -2551% respectively indicate a fundamentally unsustainable business model absent significant near-term revenue growth or capital raise.
Why Buy Sagimet Biosciences Inc. Stock? SGMT Key Strengths
- Strong balance sheet with $111.4M stockholders equity and $7.2M total liabilities
- Excellent liquidity position with 22.82x current ratio and $35M in cash reserves
- Zero long-term debt eliminates covenant pressure and refinancing risk
SGMT Stock Risks: Sagimet Biosciences Inc. Investment Risks
- Severe cash burn of $45.6M annually against $2M revenue provides less than 12 months operational runway
- Net income loss of $51M with operating margins of -2844% demonstrates completely unsustainable cost structure
- Minimal revenue base with unclear commercialization timeline or path to profitability
- Typical biotech development risk with no visibility into clinical pipeline efficacy or regulatory success
- Imminent requirement for dilutive capital raises to prevent insolvency
Key Metrics to Watch
- Quarterly revenue growth rate and timeline to reach break-even
- Monthly operating cash burn and months of remaining cash runway
- Clinical pipeline advancement and regulatory milestone achievements
Sagimet Biosciences Inc. (SGMT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 22.82x current ratio provides a solid financial cushion.
SGMT Profit Margin, ROE & Profitability Analysis
SGMT vs Healthcare Sector: How Sagimet Biosciences Inc. Compares
How Sagimet Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sagimet Biosciences Inc. Stock Overvalued? SGMT Valuation Analysis 2026
Based on fundamental analysis, Sagimet Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sagimet Biosciences Inc. Balance Sheet: SGMT Debt, Cash & Liquidity
SGMT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sagimet Biosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.45 indicates the company is currently unprofitable.
SGMT Revenue Growth, EPS Growth & YoY Performance
SGMT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.0M | -$6.4M | $-0.35 |
| Q3 2023 | $2.0M | -$6.4M | $-40.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sagimet Biosciences Inc. Dividends, Buybacks & Capital Allocation
SGMT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sagimet Biosciences Inc. (CIK: 0001400118)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SGMT
What is the AI rating for SGMT?
Sagimet Biosciences Inc. (SGMT) has an AI rating of STRONG SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGMT's key strengths?
Claude: Strong balance sheet with $111.4M stockholders equity and $7.2M total liabilities. Excellent liquidity position with 22.82x current ratio and $35M in cash reserves.
What are the risks of investing in SGMT?
Claude: Severe cash burn of $45.6M annually against $2M revenue provides less than 12 months operational runway. Net income loss of $51M with operating margins of -2844% demonstrates completely unsustainable cost structure.
What is SGMT's revenue and growth?
Sagimet Biosciences Inc. reported revenue of $2.0M.
Does SGMT pay dividends?
Sagimet Biosciences Inc. does not currently pay dividends.
Where can I find SGMT SEC filings?
Official SEC filings for Sagimet Biosciences Inc. (CIK: 0001400118) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGMT's EPS?
Sagimet Biosciences Inc. has a diluted EPS of $-1.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SGMT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sagimet Biosciences Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SGMT stock overvalued or undervalued?
Valuation metrics for SGMT: ROE of -45.8% (sector avg: 15%), net margin of -2,551.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SGMT stock in 2026?
Our dual AI analysis gives Sagimet Biosciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGMT's free cash flow?
Sagimet Biosciences Inc.'s operating cash flow is $-45.7M, with capital expenditures of N/A. FCF margin is -2,282.5%.
How does SGMT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,551.9% (avg: 12%), ROE -45.8% (avg: 15%), current ratio 22.82 (avg: 2).